{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T21:22:41Z","timestamp":1773523361128,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:00:00Z","timestamp":1767484800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:00:00Z","timestamp":1767484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-025-04854-w","type":"journal-article","created":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T03:20:09Z","timestamp":1767496809000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Selpercatinib-induced renal tubular damage resulting in symptomatic hyponatremia and polyuria: a case report"],"prefix":"10.1007","volume":"96","author":[{"given":"Lyan","family":"Betsema","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart A.W","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alwin D.R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan Paul","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,4]]},"reference":[{"key":"4854_CR1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231177015","author":"MA Gouda","year":"2023","unstructured":"Gouda MA, Subbiah V (2023) Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers. Ther Adv Med Oncol. https:\/\/doi.org\/10.1177\/17588359231177015","journal-title":"Ther Adv Med Oncol"},{"issue":"10","key":"4854_CR2","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","volume":"23","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, Wolf J, Konda B, Kang H, Spira A, Weiss J, Takeda M, Ohe Y, Khan S, Ohashi K, Soldatenkova V, Szymczak S, Sullivan L, Wright J, Drilon A (2022) Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial. Lancet Oncol 23(10):1261\u20131273. https:\/\/doi.org\/10.1016\/S1470-2045(22)00541-1","journal-title":"Lancet Oncol"},{"key":"4854_CR3","unstructured":"European Medicines Agency (2020) Summary of Products Retsevmo. Committee for Medicinal Products for Human Use. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/retsevmo-epar-product-information_en.pdf. Accessed 6 June 2024"},{"key":"4854_CR4","unstructured":"European Medicines Agency (2020) Assessment report Retsevmo. Committee for Medicinal Products for Human Use. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/retsevmo-epar-public-assessment-report_en.pdf. Accessed 4 June 2024"},{"issue":"20","key":"4854_CR5","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","volume":"389","author":"J Hadoux","year":"2023","unstructured":"Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, Gao M, Jarzab B, Isaev P, Kopeckova K, Wadsley J, F\u00fchrer D, Keam B, Bardet S, Sherman EJ, Tahara M, Hu MI, Singh R, Lin Y, Soldatenkova V, Wright J, Lin B, Maeda P, Capdevila J, Wirth LJ (2023) Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer. N Engl J Med 389(20):1851\u20131861. https:\/\/doi.org\/10.1056\/NEJMoa2309719","journal-title":"N Engl J Med"},{"issue":"36","key":"4854_CR6","doi-asserted-by":"publisher","first-page":"5582","DOI":"10.1038\/sj.onc.1205741","volume":"21","author":"DC Lee","year":"2002","unstructured":"Lee DC, Chan KW, Chan SY (2002) Ret receptor tyrosine kinase isoforms in kidney function and disease. Oncogene 21(36):5582\u201392. https:\/\/doi.org\/10.1038\/sj.onc.1205741","journal-title":"Oncogene"},{"issue":"1","key":"4854_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/kisup.2012.1","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group","year":"2012","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group (2012) KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2(1):1\u2013138 [Internet]. KI_SuppCover_2.1.indd. Accessed 30 September 2024","journal-title":"Kidney Int Suppl"},{"issue":"8","key":"4854_CR8","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s00424-022-02701-","volume":"474","author":"AM Hall","year":"2022","unstructured":"Hall AM, de Seigneux S (2022) Metabolic mechanisms of acute proximal tubular injury. Pflugers Arch 474(8):813\u2013827. https:\/\/doi.org\/10.1007\/s00424-022-02701-","journal-title":"Pflugers Arch"},{"issue":"1","key":"4854_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.5249\/jivr.v7i1.604","volume":"7","author":"D Patschan","year":"2015","unstructured":"Patschan D, M\u00fcller GA (2015) Acute kidney injury. J Inj Violence Res 7(1):19\u201326. https:\/\/doi.org\/10.5249\/jivr.v7i1.604","journal-title":"J Inj Violence Res"},{"key":"4854_CR10","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/B978-0-323-05876-6.00068-X","volume-title":"Comprehensive Clinical Nephrology","author":"L Yang","year":"2010","unstructured":"Yang L, Bonventre JV (2010) CHAPTER 68 - Diagnosis and Clinical Evaluation of Acute Kidney Injury. Comprehensive Clinical Nephrology, 4th edn. Mosby, pp 821\u2013829","edition":"4th edn"},{"key":"4854_CR11","volume-title":"Acute kidney injury (AKI)","author":"M Joseph","year":"2022","unstructured":"Joseph M, Haniff M, To KCY, Ribic CM, My\u015bliwiec M, Drabczyk R (2022) Acute kidney injury (AKI). McMaster Textbook of Internal Medicine, Krak\u00f3w"},{"issue":"6","key":"4854_CR12","first-page":"743","volume":"15","author":"CA Naughton","year":"2008","unstructured":"Naughton CA (2008) Drug-induced nephrotoxicity. Am Fam Physician 15(6):743\u2013750","journal-title":"Am Fam Physician"},{"key":"4854_CR13","unstructured":"Lilly Trials (2020) A study of selpercatinib (LY3527723) in participants with RET-mutant medullary thyroid cancer (LIBRETTO-531). Lilly Trials. https:\/\/trials.lilly.com\/en-US\/trial\/225532. Accessed 9 July 2024"},{"key":"4854_CR14","unstructured":"U.S. Department of Health and Human Services (2017) Common Terminology Criteria for Adverse Events. National Cancer Institute. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf. Accessed 9 July 2024"},{"key":"4854_CR15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239\u2013245","journal-title":"Clin Pharmacol Ther"},{"key":"4854_CR16","unstructured":"Bethesda MS (2012) LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Adverse Drug Reaction Probability Scale (Naranjo) in Drug Induced Liver Injury. [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548069\/"},{"key":"4854_CR17","doi-asserted-by":"publisher","unstructured":"Ortiz MV, Gerdemann U, Raju SG, Henry D, Smith S, Rothenberg SM, Cox MC, Proust S, Bender JG, Frazier AL, Anderson P, Pappo AS (2020) Activity of the highly specific RET inhibitor Selpercatinib (LOXO-292) in pediatric patients with tumors harboring RET gene alterations. JCO Precis Oncol 4. https:\/\/doi.org\/10.1200\/PO.19.00401","DOI":"10.1200\/PO.19.00401"},{"issue":"10","key":"4854_CR18","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s40262-023-01293-9","volume":"62","author":"MBA van der Kleij","year":"2023","unstructured":"van der Kleij MBA, Guchelaar NAD, Mathijssen RHJ, Versluis J, Huitema ADR, Koolen SLW, Steeghs N (2023) Therapeutic drug monitoring of kinase inhibitors in oncology. Clin Pharmacokinet 62(10):1333\u20131364. https:\/\/doi.org\/10.1007\/s40262-023-01293-9","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"4854_CR19","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/FTD.0b013e3181b2c8cf","volume":"31","author":"Y Wang","year":"2009","unstructured":"Wang Y, Chia YL, Nedelman J, Schran H, Mahon FX, Molimard M (2009) A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times. Ther Drug Monit 31(5):579\u201384. https:\/\/doi.org\/10.1097\/FTD.0b013e3181b2c8cf","journal-title":"Ther Drug Monit"},{"issue":"4","key":"4854_CR20","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1097\/FTD.0000000000000767","volume":"42","author":"JM Janssen","year":"2020","unstructured":"Janssen JM, Dorlo TPC, Beijnen JH, Huitema ADR (2020) Evaluation of extrapolation methods to predict trough concentrations to guide therapeutic drug monitoring of oral anticancer drugs. Ther Drug Monit 42(4):532\u2013539. https:\/\/doi.org\/10.1097\/FTD.0000000000000767","journal-title":"Ther Drug Monit"},{"key":"4854_CR21","unstructured":"National Research Council (US) Subcommittee on Biologic Markers in Urinary Toxicology (1995) Biologic Markers in Urinary Toxicology. National Academies Press. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK232061\/. Accessed 28 June 2024"},{"key":"4854_CR22","volume-title":"Prerenal kidney failure","author":"H Manzoor","year":"2023","unstructured":"Manzoor H, Bhatt H (2023) Prerenal kidney failure. StatPearls [Internet], Treasure Island"},{"key":"4854_CR23","doi-asserted-by":"publisher","unstructured":"(2022) Selpercatinib. React Wkly. https:\/\/doi.org\/10.1007\/s40278-022-29635-6","DOI":"10.1007\/s40278-022-29635-6"},{"issue":"13","key":"4854_CR24","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1056\/NEJMc2400216","volume":"4","author":"H Izzedine","year":"2024","unstructured":"Izzedine H, Bouderlique E, Besse B (2024) Selpercatinib and pseudo-decreases in kidney function. N Engl J Med 4(13):1241\u20131243. https:\/\/doi.org\/10.1056\/NEJMc2400216","journal-title":"N Engl J Med"},{"issue":"4","key":"4854_CR25","doi-asserted-by":"publisher","first-page":"c312","DOI":"10.1159\/000319885","volume":"17","author":"KD Jhaveri","year":"2011","unstructured":"Jhaveri KD, Flombaum CD, Kroog G, Glezerman IG (2011) Nephrotoxicities associated with the use of tyrosine kinase inhibitors: a single-center experience and review of the literature. Nephron Clin Pract 17(4):c312\u2013c319. https:\/\/doi.org\/10.1159\/000319885","journal-title":"Nephron Clin Pract"},{"key":"4854_CR26","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.amjopharm.2007.12.011","volume":"5","author":"A Khurana","year":"2007","unstructured":"Khurana A (2007) Allergic interstitial nephritis possibly related to Sunitinib use. Am J Geriatr Pharmacother 5:341\u2013334","journal-title":"Am J Geriatr Pharmacother"},{"key":"4854_CR27","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/ndt\/gfn625","volume":"24","author":"SK Winn","year":"2009","unstructured":"Winn SK, Ellis S, Savage P, Sampson S, Marsh JE (2009) Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect? Nephrol Dial Transpl 24:673\u2013675","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"4854_CR28","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1080\/17425255.2018.1461839","volume":"14","author":"S Cavalieri","year":"2018","unstructured":"Cavalieri S, Cosmai L, Genderini A, Nebuloni M, Tosoni A, Favales F, Pistillo P, Bergamini C, Bossi P, Licitra L, Locati LD, Alfieri S (2018) Lenvatinib-induced renal failure: two first-time case reports and review of literature. Expert Opin Drug Metab Toxicol 14(4):379\u2013385. https:\/\/doi.org\/10.1080\/17425255.2018.1461839","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"4854_CR29","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejphar.2016.02.064","volume":"15","author":"G Liamis","year":"2016","unstructured":"Liamis G, Filippatos TD, Elisaf MS (2016) Electrolyte disorders associated with the use of anticancer drugs. Eur J Pharmacol 15:777:78\u201387. https:\/\/doi.org\/10.1016\/j.ejphar.2016.02.064","journal-title":"Eur J Pharmacol"},{"key":"4854_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-56335-4","author":"X She","year":"2024","unstructured":"She X, Yin D, Guo Q, Tang Y, Wang S, Wang X (2024) Electrolyte disorders induced by six multikinase inhibitors therapy for renal cell carcinoma: a large-scale pharmacovigilance analysis. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-024-56335-4","journal-title":"Sci Rep"},{"issue":"4","key":"4854_CR31","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1177\/1078155220961551","volume":"27","author":"C Mahiat","year":"2021","unstructured":"Mahiat C, Capes A, Duprez T, Whenham N, Duck L, Labriola L (2021) Central diabetes insipidus induced by temozolomide: a report of two cases. J Oncol Pharm Pract 27(4):1040\u20131045. https:\/\/doi.org\/10.1177\/1078155220961551","journal-title":"J Oncol Pharm Pract"},{"key":"4854_CR32","doi-asserted-by":"publisher","DOI":"10.1177\/23993693231152009","author":"R Fadel","year":"2023","unstructured":"Fadel R, Tabbara J, Humi A, Nakhoul G (2023) Hypernatremia and hypokalemia with entrectinib therapy: a case of possible nephrogenic diabetes insipidus. J Onco-Nephrol. https:\/\/doi.org\/10.1177\/23993693231152009","journal-title":"J Onco-Nephrol"},{"issue":"2","key":"4854_CR33","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2215\/CJN.02740608","volume":"4","author":"S Bitew","year":"2009","unstructured":"Bitew S, Imbriano L, Miyawaki N, Fishbane S, Maesaka JK (2009) More on renal salt wasting without cerebral disease: response to saline infusion. Clin J Am Soc Nephrol 4(2):309\u2013315. https:\/\/doi.org\/10.2215\/CJN.02740608","journal-title":"Clin J Am Soc Nephrol"},{"key":"4854_CR34","volume-title":"Hyponatremia","author":"H Rondon","year":"2023","unstructured":"Rondon H, Badireddy M (2023) Hyponatremia. StatPearls [Internet], Treasure Island"},{"issue":"13","key":"4854_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1023660","volume":"3","author":"Y Xiong","year":"2022","unstructured":"Xiong Y, Wang Q, Liu Y, Wei J, Chen X (2022) Renal adverse reactions of tyrosine kinase inhibitors in the treatment of tumours: a Bayesian network meta-analysis. Front Pharmacol 3(13):1023660. https:\/\/doi.org\/10.3389\/fphar.2022.1023660","journal-title":"Front Pharmacol"},{"key":"4854_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22116109","volume":"6","author":"E Kwiatkowska","year":"2021","unstructured":"Kwiatkowska E, Doma\u0144ski L, Dziedziejko V, Kajdy A, Stefa\u0144ska K, Kwiatkowski S (2021) The mechanism of drug nephrotoxicity and the methods for preventing kidney damage. Int J Mol Sci 6:6109. https:\/\/doi.org\/10.3390\/ijms22116109","journal-title":"Int J Mol Sci"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04854-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04854-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04854-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T15:01:44Z","timestamp":1767538904000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04854-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,4]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4854"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04854-w","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,4]]},"assertion":[{"value":"17 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Informed consent was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"4"}}